

Protocol JZHB

Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

This is the trial summary as assessed on clinicaltrials.gov on 29/08/2019.

Minor changes in the protocol may occur. You can check this on this direct link:

<https://clinicaltrials.gov/ct2/show/NCT03898791?cond=Lung+Cancer%2C+Small+Cell&cntry=BE&draw=2&rank=11>

Inclusion Criteria:

Age \geq 18 years

Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.

Have adequate organ function.

Have a performance status (PS) of \leq 1 on the Eastern Cooperative Oncology Group (ECOG) scale.

Have discontinued previous treatments for cancer.

Are able to swallow capsules.

Exclusion Criteria:

Currently enrolled in a clinical study.

Have a serious concomitant systemic disorder.

Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.

Have a significant cardiac condition.

Have previously received an aurora kinase inhibitor.